Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Growth in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,577,365 shares, an increase of 49.6% from the July 15th total of 1,054,620 shares. Based on an average daily trading volume, of 1,913,836 shares, the short-interest ratio is presently 0.8 days. Currently, 22.5% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MBRX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Moleculin Biotech presently has an average rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Trading Down 6.2%

NASDAQ MBRX opened at $0.57 on Thursday. The firm has a market capitalization of $4.06 million, a PE ratio of -0.03 and a beta of 1.83. The business’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $2.40. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. As a group, analysts forecast that Moleculin Biotech will post -3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.